Recent in vivo pharmacologic studies in healthy dogs [25, 27] have provided support for development of ATR-101 in ACC and endocrine diseases such as CS and congenital adrenal hyperplasia given that ATR-101 preferentially distributes to the adrenal glands and selectively inhibits adrenal ACAT1 activity. This evidence concerns the gene ACAT1 and adrenal cortex carcinoma.